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and triglyceride assays. Plasma blood samples were obtained from consecutive
subjects referred to our clinic for diagnostic evaluation. The analyzer currently
used in our central laboratory (ADVIA 2400; Siemens, Deerfield, Ill) was used as
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tivity and specificitymeasurements were 95.7% and 61.9% (threshold value of cho-
lesterol 190 mg/dL) and 98% and 93.5% (threshold value of triglycerides 170 mg/
dL), respectively. POCT instruments are essential to perform epidemiologic studies
while avoiding transportation and storage of biologic material. The characteristics
of sensitivity and specificity as well as diagnostic accuracy make the POCT instru-
ment useful for obtaining an accurate stratification of a study population. (Transla-
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AT A GLANCE COMMENTARY
Background
The importance of plasma lipids to stratify global
cardiovascular risk is well recognized. However,
because of epidemiologic transition, most cardio-
vascular events occur in developing countries
where the prevalence of risk factors is derived
from patients referred to clinical centers.
Translational Significance
The possibility of having a low-cost device for
cholesterol and triglycerides assay used in epidemi-
ologic door-to-door studies represents a clear exam-
ple of translational medicine. The device may be
used to obtain directly reliable epidemiologic data
in the field, which is necessary to plan effective
actions to deal with noncommunicable diseases.
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death worldwide.1 The World Health Report 1999 esti-
mated that in 1998, 85% of the CV burden developed
from low- and middle-income countries.2 This contribu-
tion is projected to grow, given the consistent population
growth rates.3,4 Demographic transition and urbaniza-
tion also contribute to the increased prevalence of risk
factors.5 Both cholesterol and triglycerides plasma levels
are important parameters for assessing risk factors of
a population in epidemiologic studies.6,7
Although the developing world bears most of the
burden of world CV deaths, there are still no signs of
success in halting the CV disease epidemic in develop-
ing countries.4,8,9 Actions to deal with noncommunica-
ble diseases require consistent data on the prevalence
of risk factors to address large-scale prevention pro-
grams. This goal can be pursued only with door-to-
door epidemiologic studies, which use point-of-care
testing (POCT), as suggested by the World Health
Organization (WHO).10 In recent years, semiautomatic
POCT instruments that can measure blood levels of
cholesterol and triglycerides have been developed.
This study was performed to assess the sensitivity
and specificity of a new low-cost and manageable
POCT instrument (HPS MultiCare-in, Biochemical
System International, Arezzo, Italy) for cholesterol
and triglyceride assays.METHODS
Blood samples. The research conforms to the rele-
vant ethical guidelines for human research (Declara-tion of Helsinki). Informed consent was obtained,
and the study was approved by our Institutional Re-
view Board. According to the manufacturer, determi-
nations with the MultiCare system can be performed
in ethylenediaminetetraacetic acid (EDTA)-venous
blood samples or fresh capillary blood applied directly
to the test strip. Blood samples were then collected
into K2EDTA-containing tubes from outpatients
(n 5 636; age range, 22–69 years) referred to our
unit for diagnostic evaluation. Fresh capillary blood
samples (n 5 66) were obtained immediately before
assay in a practicability test.
Device used and quality control. The comparison
method involved daily quality controlled with sets of
cholesterol and triglyceride solutions at 2 medical de-
cision levels (106 6 2 and 262 6 5 mg/dL for choles-
terol and 88 6 2.5 and 173 6 3.5 mg/dL for
triglycerides). In addition, reference instruments were
submitted to external quality assurance services
(EQAS November 2007 to April 2008; Bio-Rad Labo-
ratory, Hercules, Calif). Bias and imprecision were
0.79 and 1.73 for cholesterol and 2.69 and 2.39 for
triglycerides, respectively.
Ten MultiCare devices and 5 different lots of reactive
strips for cholesterol (MultiCare, CH) and triglycerides
(MultiCare, TGL) were tested during the study. All mea-
surements were performed at room temperature, be-
tween 22C and 28C. Each MultiCare System device
was checked twice per day using the control solution.
The MultiCare systems were considered technically reli-
able if the values obtained were within the control range
set up by the manufacturer. Instrument absorbance was
reconsidered at the end of the study to confirm instru-
mental efficiency. The reliability of each lot of reactive
strips was tested using reference solutions (expected
range of variability set up by the manufacturer for
control materials was 625% for both cholesterol and
triglycerides).
Analytical data analysis. Imprecision study. The inter-
assay imprecision was calculated by performing 12
runs of the same fresh venous plasma-EDTA sample
on the same instrument. Different levels of cholesterol
and triglyceride concentrations were studied. The
intra-assay imprecision was calculated by performing
4 runs with the same sample on 3 different days. The
venous plasma-EDTA used for intra-assay impreci-
sion profiles was stored at 4C, and hematocrit, cho-
lesterol, and triglycerides levels were tested with
reference methods at the beginning and at the end of
the study. Intra-assay imprecision was also calculated
on control solutions provided by the manufacturer.
Imprecision values are exressed as coefficients of var-
iation.
Fig 1. Passing-Bablok comparison of methods for cholesterol
(n 5103; cholesterol range, 120–370 mg/dL) (y 5 0.9637x 1
22.547; r 5 0.942) (A). Difference between methods (B).
Fig 2. Passing-Bablok regression for cholesterol in practicability test
(n 5 32) (y 5 1.1208x – 20.677) (A). Differences in results obtained
by nonprofessionals compared with professionals (B).
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alyzer (2400; Siemens). According to the manufacturer’s
instructions, subjects with hematocrit values beyond the
35–50 range were preliminarily excluded. The compari-
son between methods was performed according to the
National Committee for Clinical Laboratory Standards
NCCLS EP910 using samples with a wide range of
cholesterol and triglycerides. Each sample was tested
twice with both the MultiCare system and the compari-
son method. Duplicate results with variability .15%
were retested, and aberrant data were excluded from
additional analysis.
Practicability test. In a practicability test, patients self-
measured their triglycerides (n 5 34) or cholesterol
(n5 32) with the MultiCare system, on capillary blood
according to the instruction manual. Immediately after-
ward, a professional operator conducted a second deter-
mination with the same instrument on a second
capillary sample. The pairs of results were then
compared.
Sensitivity and specificity. The sensitivity and specific-
ity of the MultiCare system (ROC curve data) were ob-tained by performing measurements with both the POCT
device and the comparison method on the same venous
EDTA blood sample (n 5 340). To reproduce the
conditions of epidemiologic studies, ROC curves were
performed in the total group of subjects independently
of hematocrit values.
Statistical analysis. Data shown are mean 6 standard
deviation (SD). For statistical analysis, regressions of
the method comparisons were calculated according to
the method of Passing and Bablok.11 Method differences
are presented as Bland-Altman bias plots.12 All tests
were performed using SPSS statistical software (SPSS
Inc., Chicago, Ill).RESULTS
Cholesterol. Imprecision study. The inter-assay im-
precision of the MultiCare Cholesterol system was
4.51% (range, 2.38%–8.54%) with cholesterol con-
centrations ranging between 132 and 368 mg/dL.
The range of intra-assay imprecision on venous-
EDTA blood samples was 4.72%–10.17%. The intra-assay
Fig 3. Passing-Bablok comparison of methods for triglycerides (n 5
103; range of triglycerides, 55–429 mg/dL) (y 5 0.9678x 1 7.883;
r 5 0.995) (A). Differences between methods (B).
Fig 4. Passing-Bablok regression for triglycerides in practicability test
(n5 34) (y5 0.8787x1 16.777; r5 0.993) (A). Differences in results
obtained by nonprofessionals compared with professionals (B).
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1.27% and 1.72%.
Accuracy. Three of 103 (2.91%) samples were re-
tested for aberrant data (insufficient sample on the strip).
When blood samples (n 5 103; cholesterol range, 120–
370 mg/dL) were examined within the framework of the
comparison method, the Passing-Bablok regression
equation was y 5 0.9637x 1 22.547 (95% confidence
interval [CI] for the slope, 0.89–1.031; r 5 0.942)
(Fig 1, A). The mean difference between methods was
3.53 6 4.29% (Fig 1, B).
Practicability test. In practicability testing (n5 32), the
Passing-Bablok regression equation was y 5 1.1208
x – 20.677 (95% CI for the slope, 0.9626–1.279;
r 5 0.978) (Fig 2, A). The difference in results obtained
by patients compared with professionals was 0.28%6
7.61% (Fig 2, B).
Sensitivity and specificity. When a cut-off value of 190
mg/dL was considered, the ROC value for MultiCare
was 95.7% for sensitivity and 61.9% for specificity.
Triglycerides. Imprecision study. The inter-assay
imprecision of the MultiCare triglycerides system was
3.29% (range, 1.06–7.45) with triglyceride concentra-
tions between 79 and 323 mg/dL. The range ofintra-assay imprecision was 2.4%–7.7% on the venous-
EDTA blood samples and 1.15%–1.54% on the control
solution.
Accuracy. Two samples of 103 (1.95%) were retested
for aberrant data (insufficient sample on the strip). The
method comparison performed on capillary blood
samples (n 5 103; range of triglycerides 55–429 mg/
dL) showed a Passing-Bablok regression equation of
y 5 0.9678x 1 7.883 (95% CI for the slope, 0.89–
1.031; r 5 0.995) (Fig 3, A). The mean difference
between methods was –2.36 6 4.95 (Fig 3, B).
Practicability test. In practicability testing (n5 34), the
Passing-Bablok regression equation was y 5 0.8787x 1
16.777 (95% CI for the slope, 0.9626–1.279; r 5 0.993)
(Fig 4, A). The difference in results obtained by nonpro-
fessionals compared with professionals was 1.26 6 9.86
(Fig 4, B).
Sensitivity and specificity. When a cut-off value of 170
mg/dL was considered, the ROC values for MultiCare
were 98% for sensitivity and 93.5% for specificity.
DISCUSSION
The MultiCare system is easy to learn to use by both
professionals and laypersons. A drop of capillary blood
Table I. Analytical performance of POCT device for determination of cholesterol and triglycerides
Assay Device Inter-assay Bias (%) Year (reference)
Imprecision (%)
Cholesterol
Cholestech LDX 4.0 2.1 199813
Cholestech LDX 3.0 — 200714
Cholestech LDX — 20.6 6 6.9 200215
CardioChek PA 4.4 — 200714
Accumeter 5.3 21.0 199813
Accutrend 2.5 25.6–16.6 200016
Accutrend ,5 23.2–2.5 199517
MultiCare-in 4.5 3.5 6 4.3
NCEP goals ,3 ,3 198818
Triglycerides
Cholestech LDX 2.6 — 200714
Cholestech LDX — 22 mg/dL 200619
Cholestech LDX — 219 6 9.4 200215
CardioChek PA 4.8 — 200714
Accutrend 1.4–6.1 0.9 6 12.9 200020
MultiCare-in 3.3 22.4 6 4.9
NCEP goals ,5 ,5 198818
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3 min for cholesterol and 2 min for triglyceride assays.
The necessary minimum volume is 10 mL. The han-
dling procedure is much the same as those used with
most blood glucose meters, but certain precautions
should nevertheless be taken. The user’s hands must
be washed with warm water before measurement to
avoid possible contamination with glycerol from hand
lotions, soaps, or disinfectants. In addition, the blood
drop must be obtained strictly according to the instruc-
tions. When device quality control was correct and
these simple precautions were followed, laypersons
achieved results comparable with those achieved by
professionals.
The MultiCare systems are pocket-sized reflectance
photometers, in which the intensity of the color devel-
oped from a chromogen reaction being proportional to
the concentration of the cholesterol or triglycerides in
the blood. The results of the MultiCare method
compared with the reference method demonstrated
good agreement between the 2 methods, with a mean dif-
ference of 3.5% and –2.3% for cholesterol and triglycer-
ides, respectively.
The availability of POCT lipid monitors has in-
creased in recent years (see Table I).13-20 Any POCT
must be validated for bias and imprecision to ensure
that appropriate medical decisions and population
screenings are made.21-23 Bias (inaccuracy) is defined
as disagreement between the monitor and the stan-
dardized laboratory. The National Cholesterol Educa-
tion Program (NCEP) in the United States
recommended bias goals of 3% and 5% for cholesterol
and triglycerides, respectively.18,24 Imprecision refersto the reproducibility of a test result. Imprecision goals
of 3% and 5% are the desirable specification for total
cholesterol and triglyceride laboratory methods, re-
spectively, according to the NCEP.18,24 Overall, the
analytical goals for POCT should be equivalent to
those used for laboratories to ensure that POCT use
does not compromise standards of patient care and
clinical decision making. POCT methods are not de-
signed to replace lipid determinations in professional
laboratories. In addition, it is important to acknowl-
edge that particularly in rural areas, the POCT envi-
ronment is different from the laboratory setting.
Therefore, the most recent analytical goals recommen-
ded for POCT instruments used for diabetes manage-
ment in the public health setting in Australia
considered a minimum imprecision goal of 5% for
cholesterol and 7.5% for triglycerides.25
Cholesterol, triglyceride, and blood glucose assays
are the 3 laboratory investigations required by the
WHO Stepwise approach to Surveillance, which is
a simple, standardized method for collecting, analyz-
ing, and disseminating data in WHO member coun-
tries.26 Other currently available POCT devices can
measure high-density lipoprotein and low-density lipo-
protein directly, which avoids the need for testing while
the patient is fasting. However, fasting is usually re-
quired in epidemiologic studies to obtain reliable data
on diabetes prevalence. It must be noted that multiple
operators and instruments involved in our study simu-
lated a true picture of the usual clinical setting. The
good results of the practicability test as well as the small
amount of blood needed to perform measurements
make the MultiCare instrument useful in epidemiologic
Translational Research
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thus obtaining reliable data in the field. This aspect is
crucial in developing countries in which the transfer
of biologic material from remote areas to a clinical cen-
ter may introduce a significant source of variability be-
cause of unpredictable problems in sample storage and
refrigeration. Some potential advantages of this advice
for developing country screening are that it or the test
strips do not require refrigeration, and that is small,
uses long-life batteries, and it is not costly in terms of
the device or the strips. In particular, the cost of the
tested device (Multicare-in, $48) is less compared
with other available instruments.
The instrument might also be useful for monitoring re-
sponses to therapy in a single patient. The easy operation
of the system enables patients to monitor their own blood
lipids in response to lifestyle changes, such as modified
eating and exercise patterns or other therapeutic means
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